Abstract: Antiretroviral resistance was detected in 21.5% of 93 pol sequences analyzed, with the M184I/V and K103N mutations that confer high-level resistance to NRTI and NNRTI, respectively, being the most frequent mutations.
Result: Among the 7 cases with NRTI mutations, the most common was M184I/V, which is known to confer high-level resistance to both emtricitabine (FTC) and 3TC.
Table: M184V
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Prevalence of HIV-1 Drug-Resistance Genotypes Among Unique Recombinant Forms from Yunnan Province, China in 2016-2017.
PMID: 31914782
2020
AIDS research and human retroviruses
Abstract: Mutations such as M184V/I (35.4%) in NRTIs and K103N/R/S/T (25.4%), V179D/E/T/Y (18.9%), G190A/E/R/S (13.8%), and Y181C (9.2%) in NNRTIs were common among the HIV-1 URF strains relative to other mutations.
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
PMID: 31516033
2020
AIDS research and human retroviruses
Abstract: M184V was detected pretreatment as a minority variant (9%).
Abstract: In AMBER, the nucleos(t)ide analog reverse transcriptase inhibitor (N(t)RTI) RAM M184I/V was identified in HIV-1 of one participant during D/C/F/TAF treatment.
Abstract: Only one postbaseline M184I/V RAM was observed in HIV-1 of an AMBER participant.
Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy.
Abstract: Resistance mutations were found in most patients (11/17; 64.7%) especially I82F (4/7; 57.1%) and M184V (10/17; 58.8%).
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 31774913
2020
The Journal of infectious diseases
Abstract: BACKGROUND: M184V/I cause high-level lamivudine (3TC) and emtricitabine (FTC) resistance and increased tenofovir disoproxil fumarate (TDF) susceptibility.
Abstract: CD4 count was lower both at initiation of antiretroviral therapy and at VF in participants who went on to develop M184V/I.
Abstract: CONCLUSIONS: Virus loads were similar in persons with and without M184V/I during VF on a TDF/XTC/NNRTI-containing regimen.
Abstract: In this study, we determined how M184V/I impacts virus load (VL) in patients failing therapy on a TDF/XTC plus nonnucleoside reverse-transcriptase inhibitor (NNRTI)-containing regimen.
Abstract: In vitro, L74I compensated
Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.
Abstract: The OLA-guided therapy group had pre-ART peripheral blood mononuclear cells evaluated for drug resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) at codons Lys103Asn, Tyr181Cys, Gly190Ala, and to lamivudine at Met184Val, and when at least one drug-resistant codon was detected in a participant's pre-ART specimen, clinicians were directed to prescribe protease inhibitor-based second-line ART.
Result: Testing by OLA detected and CS and/or NGS confirmed 122 mutations in 93 participants at enrollment across both study arms: 61 participants had only mutations conferring resistance to NNRTI, 15 had NNRTI resistance mutations and
Pretreatment HIV drug resistance spread within transmission clusters in Mexico City.
PMID: 31819984
2020
The Journal of antimicrobial chemotherapy
Result: Both M184V and M184I were observed mainly as low-frequency variants in approximately 0.6% of the participants.
Discussion: Moreover, consistent with previous observations, DRMs with low transmission fitness due to high replicative impairment such as M184V/I and K65R were not shared within the Mexican network, and were observed mostly at low within-host frequencies in the study population.
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.
Abstract: After several weeks, virological failure was confirmed with 4.01 HIV RNA Log copies/mL and R263K and M184V resistance mutations were detected.
HIV mutation literature information.
PMID: 
2020
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT